237 related articles for article (PubMed ID: 19185917)
1. Impact on survival of different treatments for myelodysplastic syndromes (MDS).
Nachtkamp K; Kündgen A; Strupp C; Giagounidis A; Kobbe G; Gattermann N; Haas R; Germing U
Leuk Res; 2009 Aug; 33(8):1024-8. PubMed ID: 19185917
[TBL] [Abstract][Full Text] [Related]
2. Is survival enough for myelodysplastic syndromes?
Santini V
Leuk Res; 2009 Aug; 33(8):1017-8. PubMed ID: 19268362
[No Abstract] [Full Text] [Related]
3. Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG.
Martin MG; Uy GL; Procknow E; Stockerl-Goldstein K; Cashen A; Westervelt P; Abboud CN; Augustin K; Luo J; DiPersio JF; Vij R
Bone Marrow Transplant; 2009 Jul; 44(1):13-7. PubMed ID: 19139740
[TBL] [Abstract][Full Text] [Related]
4. Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML.
Nevill TJ; Hogge DE; Toze CL; Nantel SH; Power MM; Abou Mourad YR; Song KW; Lavoie JC; Forrest DL; Barnett MJ; Shepherd JD; Nitta JY; Wong S; Sutherland HJ; Smith CA
Bone Marrow Transplant; 2008 Nov; 42(10):659-66. PubMed ID: 18679372
[TBL] [Abstract][Full Text] [Related]
5. A population-based study of survival in patients with secondary myelodysplastic syndromes (MDS): impact of type and treatment of primary cancers.
De Roos AJ; Deeg HJ; Davis S
Cancer Causes Control; 2007 Dec; 18(10):1199-208. PubMed ID: 17823848
[TBL] [Abstract][Full Text] [Related]
6. Response rate and survival after thalidomide-based therapy in 248 patients with myelodysplastic syndromes.
Candoni A; Raza A; Silvestri F; Lisak L; Galili N; Mumtaz M; Kikic F; Fanin R
Ann Hematol; 2005 Jul; 84(7):479-81. PubMed ID: 15800786
[No Abstract] [Full Text] [Related]
7. The evolution of hematopoietic SCT in myelodysplastic syndrome.
Kindwall-Keller T; Isola LM
Bone Marrow Transplant; 2009 Apr; 43(8):597-609. PubMed ID: 19252532
[TBL] [Abstract][Full Text] [Related]
8. Children with myelodysplastic syndrome (MDS) and increasing mixed chimaerism after allogeneic stem cell transplantation have a poor outcome which can be improved by pre-emptive immunotherapy.
Bader P; Niemeyer C; Willasch A; Kreyenberg H; Strahm B; Kremens B; Gruhn B; Dilloo D; Vormoor J; Lang P; Niethammer D; Klingebiel T; Beck JF
Br J Haematol; 2005 Mar; 128(5):649-58. PubMed ID: 15725087
[TBL] [Abstract][Full Text] [Related]
9. Alternatives to conventional or myeloablative chemotherapy in myelodysplastic syndrome.
Cazzola M
Int J Hematol; 2000 Aug; 72(2):134-8. PubMed ID: 11039660
[TBL] [Abstract][Full Text] [Related]
10. Favourable response to antithymocyte globulin therapy in resistant acute graft-versus-host disease.
Tagliabue A; Corti P; Viganò E; Bonanomi S; Uderzo C
Bone Marrow Transplant; 2005 Sep; 36(5):459. PubMed ID: 15980883
[No Abstract] [Full Text] [Related]
11. HLA-mismatched unrelated donors as an alternative graft source for allogeneic stem cell transplantation after antithymocyte globulin-containing conditioning regimen.
Kröger N; Zabelina T; Binder T; Ayuk F; Bacher U; Amtsfeld G; Lellek H; Schrum J; Erttmann R; Eiermann T; Zander A
Biol Blood Marrow Transplant; 2009 Apr; 15(4):454-62. PubMed ID: 19285633
[TBL] [Abstract][Full Text] [Related]
12. Treatment of pediatric myelodysplastic syndromes and juvenile myelomonocytic leukemia: the Brazilian experience in the past decade.
Valera ET; Latorre Mdo R; Mendes WL; Seber A; Lee ML; de Paula MJ; Loggetto SR; Velloso E; Niero-Melo L; Lopes LF;
Leuk Res; 2004 Sep; 28(9):933-9. PubMed ID: 15234570
[TBL] [Abstract][Full Text] [Related]
13. Management of patients with higher risk myelodysplastic syndromes.
Fukumoto JS; Greenberg PL
Crit Rev Oncol Hematol; 2005 Nov; 56(2):179-92. PubMed ID: 15979321
[TBL] [Abstract][Full Text] [Related]
14. Myelodysplasia: when to treat and how.
Larson RA
Best Pract Res Clin Haematol; 2006; 19(2):293-300. PubMed ID: 16516126
[TBL] [Abstract][Full Text] [Related]
15. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes.
Stadler M; Germing U; Kliche KO; Josten KM; Kuse R; Hofmann WK; Schrezenmeier H; Novotny J; Anders O; Eimermacher H; Verbeek W; Kreipe HH; Heimpel H; Aul C; Ganser A
Leukemia; 2004 Mar; 18(3):460-5. PubMed ID: 14712285
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome in acquired aplastic anemia treated with an intensified dose schedule of horse antilymphocyte globulin in combination with androgens.
Leleu X; Terriou L; Duhamel A; Moreau AS; Andrieux J; Dupire S; Coiteux V; Berthon C; Micol JB; Guieze R; Facon T; Bauters F
Ann Hematol; 2006 Oct; 85(10):711-6. PubMed ID: 16830141
[TBL] [Abstract][Full Text] [Related]
17. [Immunosuppressive treatment of the myelodysplastic syndrome].
Larsen MS; Hasselbalch HC
Ugeskr Laeger; 2003 Jun; 165(26):2654-7. PubMed ID: 12886548
[TBL] [Abstract][Full Text] [Related]
18. New agents in myelodysplastic syndromes.
Jabbour EJ; Giles FJ
Curr Hematol Rep; 2005 May; 4(3):191-9. PubMed ID: 15865871
[TBL] [Abstract][Full Text] [Related]
19. Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes.
Neukirchen J; Blum S; Kuendgen A; Strupp C; Aivado M; Haas R; Aul C; Gattermann N; Germing U
Eur J Haematol; 2009 Nov; 83(5):477-82. PubMed ID: 19548919
[TBL] [Abstract][Full Text] [Related]
20. Are we nearer to curing patients with MDS?
Sekeres MA
Best Pract Res Clin Haematol; 2010 Dec; 23(4):481-7. PubMed ID: 21130411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]